Evotec AG (NASDAQ:EVO) Short Interest Up 68.6% in July

Evotec AG (NASDAQ:EVO) saw a large growth in short interest in July. As of July 31st, there was short interest totaling 47,630 shares, a growth of 68.6% from the July 15th total of 28,249 shares. Based on an average daily trading volume, of 48,877 shares, the short-interest ratio is currently 1.0 days. Currently, 0.0% of the shares of the stock are short sold.

Hedge Funds Weigh In On Evotec

A number of institutional investors and hedge funds have recently modified their holdings of EVO. ABC Arbitrage SA lifted its position in shares of Evotec by 319.7% during the 4th quarter. ABC Arbitrage SA now owns 554,287 shares of the company’s stock valued at $1,707,000 after acquiring an additional 422,230 shares during the period. Wellington Management Group LLP increased its stake in Evotec by 25.7% in the fourth quarter. Wellington Management Group LLP now owns 1,797,444 shares of the company’s stock valued at $5,536,000 after purchasing an additional 367,545 shares in the last quarter. Optiver Holding B.V. increased its stake in Evotec by 598.4% in the first quarter. Optiver Holding B.V. now owns 283,576 shares of the company’s stock valued at $709,000 after purchasing an additional 242,973 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Evotec during the fourth quarter valued at about $565,000. Finally, Millennium Management LLC acquired a new position in shares of Evotec during the fourth quarter valued at about $317,000. 5.81% of the stock is currently owned by institutional investors.

Evotec News Roundup

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $4.00 price target for Evotec, implying substantial upside from recent trading levels. The firm still expects a return to profitability in the longer term, forecasting positive EPS in fiscal 2029 and 2030. HC Wainwright Weighs in on Evotec’s Q1 Earnings
• Neutral Sentiment: HC Wainwright’s current full-year consensus reference remains a loss of $0.98 per share, while its estimates call for a $0.83-per-share loss in fiscal 2026. The forecasts indicate analysts continue to expect near-term losses before a potential recovery.
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across multiple periods: Q3 and Q4 2026 estimates were reduced to losses of $0.14 per share, from losses of $0.04 and $0.02, respectively. Its fiscal 2026 estimate was cut to a $0.83 loss from $0.31, while fiscal 2029 and 2030 estimates were reduced to $0.21 and $0.28 from $0.33 and $0.48. The broad downward revisions suggest weaker expected earnings and may weigh on investor sentiment.

Evotec Stock Down 2.6%

Shares of NASDAQ:EVO opened at $1.91 on Wednesday. Evotec has a 1 year low of $1.89 and a 1 year high of $4.27. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.33 and a quick ratio of 2.21. The business’s 50-day moving average is $2.34 and its 200-day moving average is $2.77.

Wall Street Analyst Weigh In

Several analysts recently weighed in on EVO shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evotec in a research note on Tuesday, July 21st. Berenberg Bank downgraded Evotec from a “buy” rating to a “hold” rating in a research note on Thursday, July 16th. TD Cowen cut shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 target price for the company. in a report on Wednesday, July 15th. Wall Street Zen downgraded shares of Evotec from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, HC Wainwright decreased their price target on shares of Evotec from $7.00 to $4.00 and set a “buy” rating on the stock in a report on Wednesday, July 15th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $3.00.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.